Show simple item record

dc.identifier.urihttp://hdl.handle.net/11401/77062
dc.description.sponsorshipThis work is sponsored by the Stony Brook University Graduate School in compliance with the requirements for completion of degree.en_US
dc.formatMonograph
dc.format.mediumElectronic Resourceen_US
dc.language.isoen_US
dc.publisherThe Graduate School, Stony Brook University: Stony Brook, NY.
dc.typeDissertation
dcterms.abstractMultidrug resistance is a major obstacle to effective cancer chemotherapy. New-generation taxoids SB-T-1214 and SB-T-1216 have shown two to three orders of magnitude higher potency than those of paclitaxel and docetaxel against multidrug-resistant cancer cell lines. A structure-activity relationship (SAR) study has been conducted in order to test which moiety of the new-generation taxoids account for the high potency against multidrug resistant cancer cell lines. In order to selectively deliver new-generation taxoids into tumor cells, tumor-targeted drug delivery systems with a smart methyl-branched disulfide linker have been developed in the Ojima laboratory. The metabolic stability of this disulfide linker has been assessed in various solvent systems including biologically relevant cell culture media and human blood plasma via real-time kinetic analysis by 19F NMR. Polyamidoamine (PAMAM) dendrimers are attractive anticancer drug delivery vehicles, because of their well-defined architectures and biocompatible properties. Novel PAMAM dendrimer-based tumor-targeting multifunctional conjugates have been designed, synthesized, and characterized. Biological evaluations of these conjugates against various cancer cell lines have been conducted via MTT cytotoxicity assays, confocal fluorescence microscopy (CFM) imaging, and flow cytometry analysis. Potential binding sites of novel benzimidazole inhibitors with FtsZ proteins have been identified via molecular docking, homology modeling, and protein alignment for antitubercular drug discovery. Novel mechanism of action has been proposed based on the docking results. A pharmacophore-guided docking strategy has been developed for designing novel FABP inhibitors as anti-nociceptive and anti-inflammatory agents. Newly designed analogs have better binding energy scores and smaller cLogP values.
dcterms.available2017-09-20T16:51:49Z
dcterms.contributorRudick, Jonathan Gen_US
dcterms.contributorOjima, Iwaoen_US
dcterms.contributorTonge, Peter Jen_US
dcterms.contributorGupta, Ramesh C.en_US
dcterms.creatorWei, Longfei
dcterms.dateAccepted2017-09-20T16:51:49Z
dcterms.dateSubmitted2017-09-20T16:51:49Z
dcterms.descriptionDepartment of Chemistryen_US
dcterms.extent452 pg.en_US
dcterms.formatMonograph
dcterms.formatApplication/PDFen_US
dcterms.identifierhttp://hdl.handle.net/11401/77062
dcterms.issued2016-12-01
dcterms.languageen_US
dcterms.provenanceMade available in DSpace on 2017-09-20T16:51:49Z (GMT). No. of bitstreams: 1 Wei_grad.sunysb_0771E_13039.pdf: 63564939 bytes, checksum: 276c90298ed537a5b84a708ca7d7ca09 (MD5) Previous issue date: 1en
dcterms.publisherThe Graduate School, Stony Brook University: Stony Brook, NY.
dcterms.subjectChemistry
dcterms.subjectFABP, FtsZ, metabolic stability, new-generation taxoids, PAMAM dendrimer, tumor-targeting drug delivery
dcterms.titleSynthetic, Medicinal, and Computational Studies on Novel Anticancer, Antitubercular, and Anti-nociceptive Agents
dcterms.typeDissertation


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record